<DOC>
	<DOCNO>NCT00892710</DOCNO>
	<brief_summary>The purpose trial evaluate three treatment regimens patient stage IIIB/IV Non-Small Cell Lung Cancer ( NSCLC ) performance status 2 previously treat .</brief_summary>
	<brief_title>Trial Poor Performance Status Patients ( ToPPS )</brief_title>
	<detailed_description>This randomize , Phase II trial evaluate three treatment regimens patient previously untreated stage IIIB/IV Non-Small Cell Lung Cancer ( NSCLC ) performance status ( PS ) 2 . Patients randomize either pemetrexed alone , pemetrexed bevacizumab , pemetrexed , carboplatin , bevacizumab 1:1:1 fashion . All 3 regimen tolerable poor performance status patient advance NSCLC . The 3-drug regimen ( pemetrexed/carboplatin/bevacizumab ) modify lower dose carboplatin , order minimize myelosuppression . This trial conduct multiple study site .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients must &gt; =18 year age . 2 . Nonsquamous NSCLC ( adenocarcinoma large cell carcinoma ) . Mixed tumor small cell anaplastic element eligible . Mixed tumor squamous histology acceptable long squamous element dominant histology . 3 . Unresectable stage IIIB stage IV disease . Stage IIIB disease ineligible combine modality therapy ( i.e. , pleural effusion , pericardial effusion ) . 4 . ECOG performance status 2 . 5 . No prior systemic therapy stage IIIB stage IV lung cancer . 6 . Life expectancy least 12 week . 7 . Patients must measurable disease per RECIST version 1.1 ( see Section 8 ) . 8 . Laboratory value follow : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥10 g/dL Platelets ≥100,000/μL ( ≤7 day prior treatment ) AST ALT alkaline phosphatase ( ALP ) must &lt; 2.5 x ULN , &lt; 5 x ULN patient liver metastasis . Total bilirubin &lt; 1.5 x institutional ULN Calculated creatinine clearance ≥45 mL/min 9 . The ability take folic acid , Vitamin B12 , dexamethasone accord protocol . 10 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Women childbearing potential men partner childbearing potential must use effective birth control measure treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 11 . Patient must accessible treatment followup . 12 . Patients must able understand investigational nature study give write informed consent prior study entry . 1 . Squamous cell histology . Mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone unacceptable . 2 . Patients active brain metastasis . Patients receive radiation surgery brain metastasis eligible evidence central nervous system ( CNS ) disease progression , least 2 week elapse since treatment . Ideally , patient still require use seizure medication steroid . 3 . Patients major surgical procedure ( include mediastinoscopy ) , open biopsy , significant traumatic injury within 4 week begin treatment ; , anticipation need major surgical procedure course study . 4 . Women pregnant lactating . 5 . Minor surgical procedure ( exception placement portacath central venous access ) must complete least 7 day prior begin protocol treatment . 6 . History hypersensitivity active inactive excipients component treatment ( pemetrexed , bevacizumab , and/or carboplatin ) . 7 . Pulmonary carcinoid tumor . 8 . Patients proteinuria screen demonstrate either : urine protein creatinine ( UPC ) ratio ≥1.0 screening OR urine dipstick proteinuria ≥2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection , must demonstrate ≤1 g protein/24 hour eligible ) ( see Appendix B ) 9 . Patients serious non healing wound , active ulcer , untreated bone fracture . 10 . Patients evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 11 . Patients history hematemesis hemoptysis ( define bright red blood ½ teaspoon per episode ) within 1 month prior study enrollment . 12 . History myocardial infarction unstable angina within 6 month begin treatment . 13 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . 14 . New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) ( see Appendix C ) . 15 . Serious cardiac arrhythmia require medication . 16 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) within 6 month prior Day 1 treatment . 17 . History stroke transient ischemic attack ≤ 6 month prior begin treatment . 18 . Any prior history hypertensive crisis hypertensive encephalopathy . 19 . History abdominal fistula gastrointestinal perforation ≤ 6 month prior Day 1 begin treatment . 20 . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 21 . Mental condition would prevent patient comprehension nature , risk associate , study . 22 . Use nonapproved investigational agent ≤ 30 day administration first dose study drug . Patients may receive investigational anticancer treatment participate study . 23 . Past current history neoplasm entry diagnosis exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone DFS ≥5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Stage IIIB/IV</keyword>
</DOC>